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BRIEF COMMUNICATION

Outcome of Peripheral Blood Allogeneic
Hematopoietic Stem Cell Transplantation as a
Treatment Option in Patients With Severe Aplastic
Anemia Between 40 and 50 Years
Hosein Kamranzadeh Fumani, Mahdi Jalili, Soroush Rad, Davood Babakhani,
Nasrollah Maleki*, Seyed Asadollah Mousavi, Ardeshir Ghavamzadeh
Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences,
Tehran, Iran

Abstract
The frontline treatment for patients younger than 40 years with severe aplastic anemia (AA) is allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen-identical sibling donor. However, in patients
with severe AA who are older than 40 years, allogeneic HSCT has been found to be associated with increased treatmentrelated mortality and toxicity, even when matched sibling donors are used. We report our institutional experience with
allogeneic HSCT in patients with severe AA between 40 and 50 years. A total of 19 patients with severe AA were
included in the study. Overall survival (OS) and disease-free survival (DFS) were estimated using the KaplaneMeier
method. The mean age of patients at the time of transplant was 43.79 years, and 57.9% were male. The mortality rate
was 36.8%, attributed to infection (10.5%), relapse (15.8%), and renal failure (5.3%) in all cases. Acute graft-versus-host
disease (GVHD) occurred in ﬁve patients (26.3%), and chronic GVHD occurred in two patients (10.5%). The 5-year OS
was 62% and the 5-year DFS was 52%. We found that the patient’s age, platelet level prior to transplantation, and the
number of CD3 cells infused for each transplant were independent prognostic factors for OS, and the age and sex of the
patient, graft rejection, and platelet level prior to transplantation were signiﬁcant prognostic factors associated with DFS.
We recommend that immunosuppressive therapy be considered as a ﬁrst-line treatment in patients with severe AA who
are older than 40 years. Allogeneic HSCT can be considered a valid alternative option in patients whose suppression
therapy fails.
Keywords: Allogeneic, Cell transplantation, Aplastic anemia, Age

1. Introduction

A

plastic anemia is a rare clinical syndrome in
which there is a deﬁciency of red blood cells,
white blood cells, and platelets, and fatty replacement of the marrow with a near-absence of hematopoietic precursor cells [1]. It primarily occurs in
patients aged between 15 and 30 years; a second
peak is found in the 65- to 69-year-old age group [2].
The frontline treatment for patients under the age of

40 years with severe aplastic anemia is allogeneic
hematopoietic stem cell transplantation (HSCT)
from a human leukocyte antigen (HLA)-identical
sibling donor [3]. Bone marrow has been shown to
be superior to peripheral blood, as a stem cell
source, in patients with acquired aplastic anemia
undergoing a matched sibling transplant. Peripheral
blood stem cells may reduce the risk of graft failure,
whereas bone marrow may reduce the risk of
chronic GVHD [4e6].
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Unfortunately, only about 30% of patients have an
HLA-matched sibling donor, so that the use of
alternative donors including mismatched related
donors, cord blood, or unrelated donors has been
increasingly used [7]. Immunosuppressive therapy
is recommended as ﬁrst-line therapy for (a) patients
with severe aplastic anemia who do not have an
HLA-identical sibling donor, (b) patients with severe aplastic anemia who are >35e50 years old, and
(c) patients with non-severe aplastic anemia who are
transfusion dependent [8]. The current standard
ﬁrst-line immunosuppressive regimen is a combination of horse anti-thymocyte globulin (ATG) and
cyclosporine [9].
However, in patients with severe aplastic anemia
who are older than 40 years, allogeneic HSCT is
associated with treatment-related mortality and
toxicity, even when matched sibling donors are used
[10]. As a result, allogeneic HSCT in patients between 40 years and 50 years is usually only performed in speciﬁc cases. In our previous studies,
outcomes of allogeneic HSCT on adult patients with
paroxysmal nocturnal hemoglobinuria (PNH) and
Fanconi anemia were evaluated [11,12].
It has been reported that in our patients with severe aplastic anemia between 1991 and 2011, 3-year
overall survival (OS) and disease-free survival (DFS)
of allogeneic HSCT was 82% and 75%, respectively
[13]. In the present study, we evaluated the longterm survival rates among patients aged between
40 years and 50 years with severe aplastic anemia
treated with allogeneic HSCT in the Hematologye
Oncology and Stem Cell Transplantation Research
Center, Tehran, Iran.

2. Materials and methods
This single-center retrospective study was performed at the Hematology, Oncology, and Stem Cell
Transplantation Research Center, Shariati Hospital,
Tehran, Iran, from December 2006 to December
2012. All patients with severe aplastic anemia who
were 40 years or older and underwent allogeneic
HSCT were included in the study.
During the study period, a total of 19 patients were
assessed. All patients had full HLA-matched sibling
donors, and in all of them, the source of hematopoietic stem cells was peripheral blood stem cells (PB).
The conditioning regimen included intravenous (IV)
cyclophosphamide (40 mg/kg/day IV on 4 consecutive days, from Days 5 to 2) and rabbit ATG (thymoglobin, 2.5 mg/kg IV once daily on 3 consecutive
days from Days 5 to 3 in recipients of PB as source
of hematopoietic stem cells). GVHD prophylaxis
consisted of cyclosporine A and methotrexate.
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OS and DFS were estimated using the
KaplaneMeier method. Univariate analysis of OS
and DFS to calculate the hazard ratios (HRs) of each
potential prognostic factor was performed using a
Cox proportional hazard regression. Analysis was
performed using SPSS Statistics software version 24
(IBM Corp., Armonk, NY, USA).

3. Results
A total of 19 patients were enrolled in this study.
The basic characteristics of the study population are
provided in Table 1. There were eight (42.1%)
women and 11 (57.9%) men. The mean age of patients at the time of transplant was 43.79 (range,
40e50) years. The mean time from diagnosis to
transplant was 840.1 (range, 90e2705) days. The
estimation of the median follow-up with the reverse
KaplaneMeier method was 1916 days (95% conﬁdence interval [CI], 1120e∞), ranging from 12 days
to 4513 days.
Prior to transplantation, all patients were transfusion-dependent, 19 had anemia (hemoglobin < 10
g/dL), 18 had neutropenia (PMN < 1500/mL), and 19
had thrombocytopenia (<100,000/mL). Prior to
HSCT, cyclosporine and ATG were used in four
patients, and cyclosporine alone was used in 17
patients.
The observed mortality rate was 36.8% (7 cases),
attributed to infection (2 cases; 10.5%), relapse (3
cases; 15.8%), and renal failure (1 case; 5.3%). The
cause of death was unknown in one of the patients.
Acute GVHD occurred in ﬁve patients (4 patients
grade IeII and 1 patient grade IIIeIV), and chronic
GVHD occurred in two patients (limited/mild in
both patients). Graft rejection occurred in three
patients (15.8%). The 5-year OS was 62% (95% CI of
mean, 1963.129e3852.020; Fig. 1) and the 5-year DFS
was 52% (95% CI of mean, 1504.625e3440.786;
Fig. 2).
The relationship between OS and each of the
dependent variables was analyzed using Cox proportional hazards regression models. In univariate
analysis, signiﬁcant predictors of survival were age
of the patient, platelet level prior to transplantation,
the number of mononuclear cells, and CD3 cells
infused for each transplant. Multivariate analysis
conﬁrmed that the patient’s age, platelet level prior
to transplantation, and the number of CD3 cells
infused for each transplant were independent
prognostic factors for OS (Table 2).
In addition, prognostic factors associated with
DFS in all patients were also assessed using Cox
proportional hazards analysis. The results of the
unilateral analysis showed that the age and sex of
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Table 1. Basic characteristics of the study population.
Age
(y)b

Sex

1
2
3
4
5
6
7
8
9c
10
11
12
13
14
15
16
17
18
19

50
49
49
49
47
46
44
44
43
43
43
41
41
41
41
41
40
40
40

F
M
F
F
M
M
M
M
M
F
F
F
F
M
M
M
M
M
F

Prior to transplantation
WBC
(109/L)

Hb
(g/dL)

Platelets
(/mm3)

10
3.9
1.9
8
7
0.5
3.3
1.8
1.5
2
1.1
2.1
3.8
1
2.5
2.5
1.5
1.9
2.6

5.5
7
5.3
7.2
7.6
6.2
4.8
8
7.5
4.2
6.6
4.3
6.1
3.8
6.5
6.6
5.3
7.1
7.7

14,000
9000
13,000
6000
8000
6000
8000
10,000
15,000
5000
53,000
8000
28,000
2000
15,000
8000
31,000
10,000
20,000

Diagnosis to
transplantation (d)

Acute GVHD
(grade)

Chronic
GVHD

Survival
status

Rejection
(yes/no)

Cause
of death

Follow-up
time (mo)

262
2705
1714
268
473
181
90
365
1984
175
1919
148
549
225
697
2525
198
1226
258

e
3
e
e
2
e
1
e
e
e
e
e
e
e
e
1
1
e
e

e
Limited/mild
e
e
e
e
Limited/mild
e
e
e
e
e
e
e
e
e
e
e
e

Dead
Alive
Dead
Dead
Alive
Dead
Alive
Alive
Dead
Alive
Dead
Alive
Alive
Alive
Alive
Alive
Dead
Alive
Alive

No
No
No
No
No
Yes
No
Yes
Yes
No
No
No
No
No
No
No
Yes
No
Yes

Infection
e
Renal failure/toxicity
Unknown
e
Rejection
e
e
Rejection
e
Infection
e
e
e
e
e
Rejection
e
Infection

0.4
85.4
1.4
10.4
148.5
6.1
63.0
11.7
5.5
36.8
0.7
68.1
35.9
99.3
58.3
32.3
32.5
57.5
64.4

Note. F ¼ female; M ¼ male; GVHD ¼ graft-versus-host disease; Hb ¼ hemoglobin; WBC ¼ white blood cells.
a
In all patients, the conditioning regimen was cyclophosphamide plus rabbit antithymocyte globulin. In all patients, the GVHD prophylaxis regimen was methotrexate plus
cyclosporine A. In all patients, the source of hematopoietic stem cells was peripheral blood. All patients had full HLA-matched donors (sibling: 18 cases, other relatives: patient
number 10).
b
Age at transplantation.
c
Rectal cancer after transplantation occurred in patient number 9.
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Patient
numbera

HEMATOLOGY/ONCOLOGY AND STEM CELL THERAPY 2022;15:52e58

Fig. 1. KaplaneMeier curve for Overall survival (OS) in patients with severe aplastic anemia.

Fig. 2. KaplaneMeier curve for Disease-free survival (DFS) in patients with severe aplastic anemia.
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Table 2. Multivariable cox proportional hazards analysis of overall survival and disease-free survival.
Covariate

Overall survival

Disease-free survival

Univariate

Multivariate

HR (95% CI)

p

HR (95% CI)

Sex
Age

2.4 (0.53e11)
1.2 (1e1.6)

0.26
0.048*

Rejection

2.2 (0.48e9.8)

0.31

e
2.10
(1.23e3.66)
e

WBC
Hb
Platelet

1.1 (0.82e1.5)
1.1 (0.59e1.9)
1.1 (1e1.1)

0.45
0.86
0.058*

Dx to Tx
Donor age
Nucleated WBC
MNC

1 (1e1)
1 (0.96e1.1)
0.9 (0.64e1.3)
0.71 (0.44e1.1)

0.57
0.42
0.55
0.16*

CD34
CD3

1.1 (0.86e1.4)
0.99 (0.99e1)

0.47
0.069*

Hospitalization
ANC engraftment
Platelet engraftment
Acute GVHD
Chronic GVHD
PC prior to HSCT
Platelet prior to HSCT

0.96 (0.85e1.1)
0.96 (0.84e1.1)
1 (0.97e1.1)
0.5 (0.06e4.2)
4.4  109 (0e∞)
1 (0.66e1.6)
1.1 (0.74e1.8)

0.58
0.53
0.5
0.52
1
0.9
0.55

e
1.19
(1.03e1.37)
e
e
e
1.21
(0.46e3.2)
e
0.99
(0.97e0.99)
e
e
e
e
e
e
e

Univariate

Mulrivariate

p

HR (95% CI)

p

HR (95% CI)

p

0.008**

2.5 (0.67e9.4)
1.2 (0.97e1.4)

0.18*
0.11*

3190 (2.73e3.72  106)
10.44 (1.14e95.7)

0.025**
0.038**

e

4.5 (1.2e17)

0.029*

0.043**

e
e
0.015**

1.1 (0.79e1.4)
1.4 (0.79e2.4)
1.1 (1e1.1)

0.68
0.26
0.046*

1.022  107
(1.59e6.54  1013)
e
e
1.48 (1.01e2.18)

e
e
0.046**

e
e
e
0.692

1 (1e1)
1 (0.97e1.1)
1 (0.76e1.4)
0.8 (0.51e1.3)

0.9
0.3
0.78
0.34

e
e
e
e

e
e
e
e

e
0.023**

1.1 (0.85e1.3)
1 (0.99e1)

0.64
0.11*

e
0.99 (0.98e1.05)

e
0.71

e
e
e
e
e
e
e

0.98 (0.89e1.1)
0.96 (0.86e1.1)
1 (0.96e1.1)
0.34 (0.042e2.7)
4.4  109 (0e∞)
1.1 (0.72e1.6)
1.1 (0.77e1.6)

0.64
0.47
0.71
0.31
1
0.77
0.57

e
e
e
e
e
e
e

e
e
e
e
e
e
e

Note. ANC ¼ absolute neutrophil count; CD ¼ cluster of differentiation; Dx ¼ diagnosis; GVHD ¼ graft-versus-host disease; Hb ¼
hemoglobin; HR ¼ hazard ratio; HSCT ¼ hematopoietic stem cell transplantation; MNC ¼ mononuclear cell; PC ¼ packed red blood
cells; Tx ¼ treatment; WBC ¼ white blood cells.
*
A p-value < 0.20 in the univariate analysis was included in the multivariate analysis.
**
A p-value < 0.05 in the multivariate analysis was considered statistically signiﬁcant.

the patient, graft rejection, platelet level prior to
transplantation, and the number of CD3 cells
infused for each transplant were independent predictors of DFS. Multivariate analysis revealed
that the age and sex of the patient, graft rejection,
and platelet level prior to transplantation were signiﬁcant prognostic factors associated with DFS
(Table 2).

4. Discussion
In this retrospective study, we studied the outcomes of HSCT on patients with severe aplastic
anemia who were aged between 40 and 50 years in
our center to have an estimation of general outcome
of these diseases. Kim et al. [14] retrospectively
analyzed the effect of age on transplantation outcomes and survival in 225 adult patients with
aplastic anemia who underwent allogeneic HSCT:
57 patients aged >40 years and 168 patients aged
40 years. The favorable prognostic factors in all
patients included age at HSCT of 40 years, time
from diagnosis to HSCT of 6 months, and
matched-related donor. The only poor prognostic

factor associated with survival in elderly patients
was age older than 40 years. Survival in patients
younger than 50 years was not signiﬁcantly different
in both groups [14].
A study conducted by Giammarco et al. [15]
compared the outcome of patients with severe
aplastic anemia who were older than 40 years,
transplanted in 2001 to 2009 (n ¼ 329), with patients
transplanted in 2010 to 2015 (n ¼ 439). In that study,
the authors showed that survival remained unchanged over the past 15 years in patients with severe
aplastic anemia who were older than 40 years undergoing allogeneic HSCT. They found that the patient’s age, use of either ATG or alemtuzumab in the
conditioning regimen, center experience, and donor
type were signiﬁcant prognostic factors associated
with survival. Overall, the results of this study
showed that allogeneic transplants for severe aplastic
anemia in patients older than 40 years have a significant risk of mortality, despite changes in conditioning regimens and donor type, and also in patients
receiving an HLA identical sibling transplant [15].
It has been reported that the favorable outcome of
allogeneic HSCT for patients with severe aplastic
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anemia can be attributable to the use of conditioning regimen with cyclophosphamide and ATG, the
use of GVHD prophylaxis with short-term cyclosporine and methotrexate, the use of irradiated
blood products, and the use of a leukocyte-reduction ﬁlter at the time of transfusion [16]. The optimal
conditioning regimen for aplastic anemia patients
undergoing bone marrow transplantation from an
HLA-matched unrelated donor is uncertain, but
currently a combination of ATG and cyclosporine A
is favored for older patients [17].
Graft failure or graft rejection after allogeneic
HSCT is an important and life-threatening complication in patients with aplastic anemia, especially in
those who have been heavily transfused. It has been
found that adding total lymphoid or total body
irradiation to cyclophosphamide reduced the risk of
graft failure to less than 5%, but rates of secondary
malignancies, interstitial pneumonia, and GVHD
were higher [18]. In our center, graft rejection
occurred in three patients (15.8%). In a study by
Champlin et al. [19], graft failure was evaluated in
625 patients with severe aplastic anemia who underwent allogeneic HSCT from HLA-identical sibling donors. Graft failure occurred in 68 (11%) of the
patients. The main factors associated with a reduced
risk of graft failure included the use of radiation for
conditioning regimen and use of cyclosporine or Tcell depletion for GVHD prophylaxis. The most
important factors associated with improved survival
included posttransplant treatment with cyclosporine
as GVHD prophylaxis and avoidance of pretransplant blood transfusions. The interesting thing was
that although the use of radiation in conditioning
regimen reduced graft failure, it did not improve
survival [19].
The cause of mortality in our study was infection
(10.5%), relapse (15.8%), and renal failure (5.3%).
Unlike previous studies, chronic GVHD was not the
major cause of death in our study. In another study,
Deeg et al. [20] evaluated 212 patients with aplastic
anemia transplanted who survived more than 2
years and who were followed for up to 26 years.
Lung disease occurred in 24%, bone and joint
problems in 18%, skin problems in 14%, and cataracts in 12% of patients. They found that the leading
cause of morbidity and mortality is chronic GVHD.
The probability of survival at 20 years for patients
with chronic GVHD was 69%, whereas for patients
without chronic GVHD it was 89% [20].

5. Conclusion
Given the signiﬁcant risk of mortality after allogeneic HSCT, immunosuppressive therapy should
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be considered as a ﬁrst-line treatment in patients
with severe aplastic anemia who are older than 40
years. We recommend that allogeneic HSCT from
an HLA-identical sibling donor be considered as a
valid alternative option in patients whose suppression therapy fails, although there is no sufﬁcient
evidence to routinely recommend allogeneic HSCT.
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